Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. The registrational study assessed BHV-7000, a drug designed to selectively activate Kv7.2/Kv7.3 ...

NEW YORK, NY / ACCESS Newswire / March 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd.

NEW YORK, NY / ACCESS Newswire / March 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Topline results from the MDD study are expected in the second half of 2025, and topline data from the focal epilepsy studies (NCT06309966 and NCT06132893) are expected in early 2026. Biohaven ...

We recently published a list of 12 Stocks with Heavy Insider Buying in 2025. In this article, we are going to take a look at ...

Biohaven completed interactions with FDA enabling registrational programs for Parkinson's disease and the prevention of ARIA. Initiate BHV-8000 Phase 2/3 study in Parkinson's disease in 1H 2025.

Biohaven (BHVN) is jumping 10% after the FDA ... speech and swallowing," according to BHVN. In a three-year study, the rate of decline of patients taking troriluzole was 50%-70% slower than ...

study. Troriluzole has a well-established safety profile and if approved, would be the first and only FDA-approved treatment for SCA; subject to receipt of FDA approval, Biohaven is prepared to ...

Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression on the ...